MammaPrint

Our ever-globalising world brings with it a number of healthcare concerns, and  instances of cancers, in particular, appear to be on the rise. Cancers figure among the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012. The World Health Organisation estimates that the number of new cases is expected to rise by around 70 per cent over the next 2 decades.

MammaPrint

Improved breast cancer diagnosis and treatment

Determining most at risk

Within our societies it is widely recognized that breast cancer is one of the most common cancers amongst women. Cancer researchers, Professors Rene Bernards Ph.D. and Laura van’t Veer Ph.D. of the Netherlands Cancer Institute in Amsterdam (NKI), sought to answer one of the most important clinical questions in breast cancer management: “which patients are at risk for recurrence?”

Early stage breast cancer test

MammaPrint is the first FDA-cleared breast cancer genomic test that classifies an early stage breast cancer tumour as having either a Low Risk or High Risk of recurrence. MammaPrint can also help to identify which patients may safely forego chemotherapy, and to determine the optimal treatment approach for each patient. After the diagnosis, patients and physicians together decide on the subsequent course of action.

Sustainable Urban Delta

The inherent complexities and pressures associated with densely populated urban areas are second nature to the Dutch. Over many centuries, authorities, industries, knowledge institutes, and citizens have striven to develop integrated approaches and a holistic vision to enable sustainable development of the urban environment – the Sustainable Urban Delta.